New Novartis blood cancer drug approved in EU
Novartis | September 20, 2017
For the first time, patients with a rare and life-threatening blood disorder have a treatment option after Novartis’ Rydapt got an EU licence for aggressive systemic mastocytosis, related blood cancers, and acute myeloid leukaemia.